This Durban CTU application is underpinned by a central administrative hub that serves the 3 HIV Clinical Research Sites included in this application. They bring together 3 major disciplines, most affected by the rising morbidity and mortality from HIV/AIDS viz. adult medicine, pediatrics, and obstetrics and gynecology from the University of KwaZulu-Natal, to develop and promote research into Translational Drug Research, Optimization of Clinical Management and Co-morbidities and to complement prevention and vaccine research programs in the region. The Principal Investigator, Prof. Umesh Lalloo, (also Site Leader for the Adult HIV Research Clinic) is supported by site experienced Site Leaders for the other research clinics proposed. Administration, Pharmacy, Lab Services and Data Management are the shared resources for all three sites. The long-term objectives are to: 1. Promote development of new strategies (drugs, immunomodulation, and regimens) to simplify the complex treatment of HIV/AIDS, given the immense impact of the epidemic in resource limited settings. This will ensure optimal treatment options in a Clade C HIV epidemic and where the threat of ARV drug resistance is serious and drug interactions are important, given the multiple co-morbidities 2. Promote the development of optimal strategies to treatment the complications of HIV, which contributes to the rising morbidity and mortality 3. Promote the development of scientific and clinical research expertise in resource limited settings in individuals from previously disadvantaged groups.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069426-05
Application #
8034716
Study Section
Special Emphasis Panel (ZAI1-BLG-A (M1))
Program Officer
Pouliot, Eileen M
Project Start
2007-03-01
Project End
2014-01-31
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
5
Fiscal Year
2011
Total Cost
$2,429,118
Indirect Cost
Name
Ukzn Innovation
Department
Type
DUNS #
638919600
City
Durban
State
Country
South Africa
Zip Code
4001
Murphy, M E; Wills, G H; Murthy, S et al. (2018) Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study. BMC Med 16:189
Tweed, Conor Duncan; Wills, Genevieve Helen; Crook, Angela M et al. (2018) Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med 16:46
Murthy, S E; Chatterjee, F; Crook, A et al. (2018) Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis. BMC Med 16:73
Phillips, Patrick P J; Mendel, Carl M; Nunn, Andrew J et al. (2017) A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens. BMC Med 15:207
Murphy, Michael E; Phillips, Patrick P J; Mendel, Carl M et al. (2017) Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis. BMC Med 15:192
Robertson, K; Jiang, H; Evans, S R et al. (2016) International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol 22:472-8
Firnhaber, Cynthia; Smeaton, Laura M; Grinsztejn, Beatriz et al. (2015) Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials 16:89-99
Thio, Chloe L; Smeaton, Laura; Hollabaugh, Kimberly et al. (2015) Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS 29:1173-82
Hitti, Jane; Halvas, Elias K; Zheng, Lu et al. (2014) Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207. J AIDS Clin Res 5:
Safren, Steven A; Biello, Katie B; Smeaton, Laura et al. (2014) Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One 9:e104178

Showing the most recent 10 out of 26 publications